Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance-Reference-Cited by-同舟云学术

Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance

Published:2022-01-05 Issue: Volume: Page:
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Fallani Elettra¹,Cevenini Fabio²,Lazzerini Pietro Enea³,Verdini Annalisa⁴,Saponara Simona¹^ORCID

Affiliation:

1. Dipartimento di Scienze della Vita Università di Siena Siena Italy

2. Dipartimento di Economia e Management Università di Trento Trento Italy

3. Dipartimento di Medicina Chirurgia e Neuroscienze Università di Siena Siena Italy

4. Dipartimento del Farmaco Azienda USL Toscana Sud Est Siena Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2006

Reference71 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

2. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

3. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

4. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

5. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of gastrointestinal side effects in COVID-19 patients undergoing combined pharmacological treatment with azithromycin and hydroxychloroquine: a systematic review and network meta-analysis;Critical Reviews in Toxicology;2024-06-11

2. The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System;Saudi Pharmaceutical Journal;2023-07

3. Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-06-26

4. Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies;European Journal of Clinical Pharmacology;2023-04-20

5. Caracterización de los eventos adversos a hidroxicloroquina, ivermectina, azitromicina y tocilizumab en pacientes hospitalizados por la COVID-19 en un hospital del Seguro Social de Salud del Perú;Revista Peruana de Medicina Experimental y Salud Pública;2023-03-28